Doxy ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05521048 (ClinicalTrials.gov) | September 19, 2022 | 26/8/2022 | Doxycycline in Cutaneous Schwannoma (NF2) | Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2 | Neurofibromatosis Type 2 | Drug: Doxycycline Injection [Doxy] | Massachusetts Eye and Ear Infirmary | NULL | Recruiting | 8 Years | N/A | All | 19 | Phase 1/Phase 2 | United States |